SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

COGT

Cogent Biosciences, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The APEX data are strong and the NDA submission timeline is near-term (June 2026), which de-risks the regulatory path. Traders should watch for FDA acceptance of the NDA and any AdCom vote as the next catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$33.10
T+0 close · Jun 12, 2026 · via day close
Latest settled
+6.59%
T+60 · $35.28
Vs SPY
+3.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $33.10entry
  2. T+1 · 5mo ago +0.21%α −1.55% · $33.17
  3. T+5 · 5mo ago +4.35%α +3.68% · $34.54
  4. T+20 · 4mo ago +17.43%α +15.65% · $38.87
  5. T+60 · 2mo ago +6.59%α +3.32% · $35.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvSM) at EHA 2026, showing a 65% objective response rate per mIWG criteria and 81% per PPR criteria, with 91% of patients achieving ≥50% reduction in KIT D816V variant allele frequency. The company plans to submit an NDA in June 2026 and expects commercial launch later this year.

Key Facts

  • Updated APEX trial data: 65% ORR per mIWG criteria (CR+CRh+PR+CI) and 81% ORR per PPR criteria in AdvSM patients.
  • 91% of patients achieved ≥50% reduction in KIT D816V variant allele frequency; 89% had ≥50% reduction in bone marrow mast cells or clearance of aggregates.
  • 12-month PFS rate of 79% and 12-month OS rate of 87%.
  • NDA submission for bezuclastinib in AdvSM planned for June 2026.
  • Company expects commercial launch in both systemic mastocytosis and GIST later this year following FDA approval.
  • Safety profile manageable: most common TRAEs were hair color change (31%), neutropenia (31%), altered taste (28%), thrombocytopenia (25%), and ALT/AST elevations (21%), mostly low-grade.

Financial Impact

No financial data provided; bezuclastinib is Cogent's lead asset and potential approval would transform the company from pre-revenue to commercial-stage. Systemic mastocytosis and GIST represent multi-billion-dollar market opportunities.

revenueepscash_runway

Risk Factors

  • FDA could issue a Complete Response Letter (CRL) on CMC or clinical grounds, delaying approval.
  • Competition from approved KIT inhibitors (e.g., avapritinib) could limit commercial uptake.
  • Commercial launch execution risk for a first-time product.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311014

Track record

13 reports on COGT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.18% at T+20 after the May 30, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Viewing Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026